SynthesisBMC women's health2026
The role of mifepristone in managing myoma: a systematic review and meta-analysis of uterine parameters.
Synthesis in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMifepristone has demonstrated favorable effects in managing uterine myomas, particularly for patients aiming to preserve fertility. This study evaluates the effect of Mifepristone on uterine parameters, including uterine volume and endometrial thickness, across different dosages.
methodsA systematic review and meta-analysis were conducted by searching PubMed, Web of Science, Scopus, Embase, Cochrane Library, and clinical trial registries up to November 30, 2024. Eligible studies were randomized controlled trials (RCTs) comparing Mifepristone with placebo, other drugs, or different Mifepristone dosages in patients with uterine myoma. The primary outcomes were changes in uterine volume and endometrial thickness. Secondary outcomes included symptom relief, such as dyspareunia. Data were pooled using a random-effects model, and effect sizes were expressed as standardized mean differences (SMD) or relative risks (RR) with 95% confidence intervals (CI).
resultsFourteen RCTs involving a total of 1260 patients were included. Higher doses of Mifepristone (10 mg daily) compared to lower doses (5 mg daily) were associated with greater, albeit non-significant, reductions in uterine volume (SMD: -0.08, 95% CI: -0.25 to 0.09, p = 0.35) and a non-significant increase in endometrial thickness (SMD: 0.22, 95% CI: -0.23 to 0.66, p = 0.34). The 10 mg dose was significantly more effective in resolving dyspareunia (RR: 1.87, 95% CI: 1.59 to 2.20, p < 0.01).
conclusionOur analysis indicated that Mifepristone was associated with a non-significant reduction in uterine volume among patients with uterine myoma. However, higher daily doses (10 mg) demonstrated greater clinical benefits in relieving dyspareunia, despite minimal changes in uterine size. These findings suggest that higher doses (10 mg daily) may be a consideration for symptom relief, particularly for dyspareunia, despite minimal changes in uterine size. This suggestion is preliminary, given the non-significant primary outcomes and low certainty of evidence for key comparisons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.